Focus on Cancer-logo

Focus on Cancer

ReachMD

ReachMD takes a closer look at the latest advances in cancer research, diagnosis, and treatment.

ReachMD takes a closer look at the latest advances in cancer research, diagnosis, and treatment.
More Information

Location:

United States

Networks:

ReachMD

Description:

ReachMD takes a closer look at the latest advances in cancer research, diagnosis, and treatment.

Language:

English


Episodes

Pancreatic Cancer: The Hunt to Catch a Silent Killer

8/12/2017
More
Host: John J. Russell, MD Guest: Harish Lavu, MD Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations. Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the...

Duration: 00:16:30


FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

7/28/2017
More
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

Duration: 00:05:59


FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

7/25/2017
More
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

Duration: 00:08:59


The CAM Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing

7/17/2017
More
Host: Kathy King, RDN Guest: Lise Alschuler, ND Host Kathy King sits down with Dr. Lise Alschuler, naturopathic doctor, cancer survivor, and author of The Definitive Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing. Dr. Alschuler is co-founder of iTHRIVEplan.com, a web application providing personalized wellness plans tailored to cancer survivors. They talk about how integrative medicine specialists approach cancer: its causes, prevention strategies, and ways...

Duration: 00:20:29


Linking p53 Variation to Breast Cancer Risk in African American Women

6/19/2017
More
Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in...

Duration: 00:15:00


FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

5/30/2017
More
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Released May 30, 2017.

Duration: 00:05:59


FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

5/22/2017
More
FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma. Released May 22, 2017

Duration: 00:06:28


The Financial Burden of Cancer: Report from the American Cancer Society

5/22/2017
More
Host: Brian P. McDonough, MD, FAAFP Host Dr. Brian McDonough chats with Jennifer Singleterry, Senior Analyst of Policy and Legislative Support for the American Cancer Society's Cancer Action Network, about the organization's new report revealing monetary burdens for cancer patients.

Duration: 00:12:30


FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

5/18/2017
More
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Released May 18, 2017

Duration: 00:05:59


FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

5/17/2017
More
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies. Released May 17, 2017

Duration: 00:04:59


Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer

4/17/2017
More
Host: Matt Birnholz, MD Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide. Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Medicine, about new screening guidelines for detecting colorectal cancer.

Duration: 00:14:30


Improving Surveillance for Colorectal Cancer in IBD Patients

3/6/2017
More
Host: Caren Heller, MD Guest: Francis Farraye, MD Studies have shown that certain patients living with inflammatory bowel disease, or IBD, have a higher risk of developing colorectal cancer. In fact, IBD ranks as the third highest risk factor for the development of colorectal cancer. Host Dr. Caren Heller, Chief Scientific Officer at the Crohn's & Colitis Foundation, sits down with Dr. Francis Farraye, gastroenterologist and Professor of Medicine and Co-Director of the Center for...

Duration: 00:17:59


A Thoracic Surgeon's Viewpoint on Screening, Diagnosis and Treatment of a Lung Cancer Patient

2/2/2017
More
Host: Matt Birnholz, MD Guest: Taine Pechet, MD Dr. Taine Pechet, chief of surgery at Penn Presbyterian Medical Center and associate professor of clinical surgery at Penn Medicine joins host Dr. Matt Birnholz to discuss his thoughts on who should be regularly screen for lung cancer and the various diagnostic techniques from his perspective as a thoracic surgeon. Dr. Pechet also discusses the surgical outcomes for these patient and his thoughts on what is on the horizon for the lung...

Duration: 00:15:00


HPV Vaccine: A Systematic Review of 10 Years of Real-World Experience

10/11/2016
More
Host: Susan J. Wysocki, WHNP, FAANP Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience Clinical Infectious Disease 16 Aug 15;63(4):519-27. doi: 10.1093/cid/ciw354. Epub 2016 May 26. Garland SM1, Kjaer SK2, Muñoz N3, Block SL4, Brown DR5, DiNubile MJ6, Lindsay BR6, Kuter BJ6, Perez G7, Dominiak-Felden G8, Saah AJ6,Drury R8, Das R6, Velicer C6. Abstract: Prophylactic human papillomavirus (HPV) vaccination...

Duration: 00:04:30


APMs in Cancer Care: The Patient-Centered Oncology Payment Model

8/12/2016
More
Host: Matt Birnholz, MD Guest: Robin Zon, MD, FACP Value-based, patient-centered care has become the destination for all branches of medicine, and is the philosophy driving modern payment reform initiatives like MACRA. But the unique care delivery needs in each specialty challenge the notion that one payment model can serve everyone. And nowhere has this become more relevant than in the field of oncology. Dr. Matt Birnholz joins Dr. Robin Zon, practicing oncologist and vice president and...

Duration: 00:21:59


Cervical Cancer & Co-testing: What is the Economic Impact?

7/29/2016
More
Host: John J. Russell, MD Guest: Michael Randell, MD In this special edition of Advances in Women’s Health, Dr. Michael Randell shares his insights on cervical cancer testing and whether performing two cervical cancer tests is really more expensive than one from both clinical and economic standpoints. Join host Dr. John Russell for this informative discussion. Click here to learn more about other women's health programs in this special series.

Duration: 00:11:59


New Recommendations for Colorectal Cancer Screening

6/20/2016
More
[Read the Article] The U.S. Preventative Services Task Force has updated the recommendations regarding colorectal cancer screening. The Task Force strongly recommends screening average risk adults age 50 to 75 for colorectal cancer, and then making individual screening decisions for adults age 76 to 85, taking into account the patient's overall health and screening history.Colorectal cancer is the second leading cause of cancer death in the United States, and about one-third of adults in...

Duration: 00:01:00


How Dietary Choices Can Influence Cancer Outcomes

6/6/2016
More
Host: Kathy King Guest: Diana Noland How can our dietary choices affect and even influence cancer outcomes? Host Kathy King talks with Diana Noland, dietitian and board-certified clinical nutritionist on the adjunct faculty of the University of Kansas Medical Center Department of Dietetics and Nutrition, and in private practice in Burbank, CA. Ms. Noland specializes in nutritional health for complex metabolic conditions, oncology, gastrointestinal, and neurologic chronic diseases. She...

Duration: 00:16:59


Breast Cancer's Reality Check: Separating Facts from Fiction for Patients

6/6/2016
More
Host: Jennifer Caudle, DO There are many widely circulated myths regarding breast cancer, such as: Beliefs that this disease affects women only. Fears that mammograms can cause cancers to spread. Assumptions that most patients with breast cancer have family histories positive for this disease. Host Jennifer Caudle talks with guest Dr. Monique Gary, a fellowship-trained breast surgical oncologist at Grand View Health in Sellersville, Pennsylvania. Together, they dispel myths about breast...

Duration: 00:10:00


New Treatment for Advanced Melanoma Shows Promise

4/21/2016
More
[Read the Article] In a new study, researchers from the University of California-Los Angeles studied tumor response and overall survival following the administration of a new treatment among patients with advanced melanoma. This agent, called pembrolizumab, is an antibody that blocks PD-1, a protein which prevents the body's immune system from attacking the cancer.The researchers tested pembrolizumab on more than 650 patients in North America, Europe and Australia. They looked at tumor...

Duration: 00:01:00

See More